$IPA Additional evaluation of virus neutralization potency in an in vitro pseudovirus-based assay revealed that IPA's TATX-03 anti-SARS-CoV-2 antibody cocktail is also not affected by the rapidly spreading Delta variant (B.1.617.2). Parallel reactivity screening of the individual antibodies of TATX-03 revealed differential susceptibility of the lead components towards the Delta (B.1.617.1) variant with the majority showing maintained binding. These results are consistent with previously announced binding data towards other SARS-CoV-2 mutants, including variants of concern Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) variants. These binding data, combined with the maintained neutralization potency of IPA's TATX-03 to variants of concern, supports the Company's expectation that rationally designed multi-membered antibody cocktails are more sustainable, e.g. will be functionally less prone to escape-by-one mutations. https://www.barchart.com/story/news/2100303/immunoprecises-polytopetm-tatx-03-antibody-cocktail-potently-neutralizes-sars-cov-2-delta-variant-in-in-vitro-pseudovirus-assays